Subtle Medical secured $33M in growth capital led by Morgan Stanley Expansion Capital, bringing total funding to roughly $86M, and named a new CEO. Co-founder Enhao Gong moves to chief science officer. The raise follows FDA clearance days earlier for SubtleHD, its next-generation AI PET image-enhancement product. Subtle wants to become a vendor-neutral AI infrastructure layer for medical imaging spanning MR, PET, and a planned expansion into CT. The leadership change alongside the capital frames a transition from R&D-led growth toward commercial scaling.